Please assess the completion status of the following clinical trial:

Trial Title: A Study of Enfortumab Vedotin in Japanese Subjects With Locally Advanced or Metastatic Urothelial Carcinoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subject must have histologically confirmed, locally advanced (TNM classification T3b and any N; or T and N2-3) or metastatic Transitional Cell Carcinoma of the Urothelium (TCCU) (i.e., cancer of the bladder, renal pelvis, ureter, or urethra). Subjects with Urothelial Carcinoma with squamous differentiation or mixed cell types are eligible.~* Subject must be able to submit a tumor tissue samples for Nectin-4 expression analysis at central laboratory.~* Subject must have failed at least one prior chemotherapy regimen for advanced disease. Urothelial and bladder cancer subjects are not required to have failed prior chemotherapy regimen if considered unfit for cisplatin-based chemotherapy.~* Subject must have measurable disease according to Response Evaluation Criteria in Solid Tumor (RECIST) (version 1.1).~* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.~Exclusion Criteria:~* Preexisting sensory neuropathy Grade ≥ 2.~* Preexisting motor neuropathy Grade ≥ 2.~* Uncontrolled central nervous system metastasis that requires active treatment.~* Any anticancer therapy within 14 days prior to the first dose of study drug.~* Subjects with pre-existing immunotherapy-related adverse events requiring high doses of systemic steroids are not eligible.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm A: Enfortumab vedotin 1.0 mg/kg (Type: EXPERIMENTAL): All subjects assigned will receive a single 30 minute intravenous infusion of enfortumab vedotin (ASG-22CE) once weekly for 3 weeks of every 4 weeks (i.e., on Days 1, 8, and 15). A cycle is 28 days.
- Arm B: Enfortumab vedotin 1.25 mg/kg (Type: EXPERIMENTAL): All subjects assigned will receive a single 30 minute intravenous infusion of enfortumab vedotin (ASG-22CE) once weekly for 3 weeks of every 4 weeks (i.e., on Days 1, 8, and 15). A cycle is 28 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).